Physician profile
Harry G Lim
NPI 1336199884
$1,512.41
in general payments reported to CMS, 2019-2025
25 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $66.85 · 2022: $50.95 · 2023: $280 · 2024: $505 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $216.03 | 2019-2025 | |
| Edwards Lifesciences Corporation | $157.28 | 2019-2024 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $136.25 | 2019-2023 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $111.88 | 2019-2024 | Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $110.56 | 2024-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $108.86 | 2019-2024 | Xarelto |
| Pfizer INC. | $87.77 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $57.30 | 2019-2023 | Evkeeza |
| Bayer Healthcare Pharmaceuticals INC. | $56.89 | 2025 | |
| Merck Sharp & Dohme LLC | $52.66 | 2024 | Verquvo |
| Amgen INC. | $51.16 | 2022-2023 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $45.69 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.78 | 2019-2023 | Jardiance |
| Altathera Pharmaceuticals LLC | $40.74 | 2022-2023 | Sotalol Hydrochloride |
| Scpharmaceuticals INC. | $35.41 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $31.37 | 2019-2020 | |
| Novo Nordisk INC | $26.27 | 2025 | Ozempic |
| Integra Lifesciences Corporation | $24.15 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Atricure, INC. | $23.16 | 2025 | Synergy Ablation System |
| La Jolla Pharmaceutical Company | $19.42 | 2025 | Giapreza |
| Alnylam Pharmaceuticals INC. | $19.08 | 2024 | Onpattro |
| Sanofi-Aventis U.S. LLC | $16.49 | 2019 | |
| Lantheus Medical Imaging, INC. | $15.50 | 2019 | |
| Hemosonics LLC | $13.33 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.